Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 36 in Nanobiotix

  1. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market Trends...Read the original story

    Monday Apr 20 | PR-inside.com

    ... Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG, Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex Medical Limited. Request TOC of "Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market ...

    Comment?

  2. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market...Read the original story w/Photo

    Monday Apr 20 | PR-inside.com

    ... Merit Medical Systems, Inc., EmboMedics Inc., Eckert & Ziegler BEBIG, Kobo Products, Inc., Polysciences Inc., Nanobiotix, Mo-Sci Corporation and Sirtex Medical Limited. About Grand View Research Grand View Research, Inc. is a market research and ...

    Comment?

  3. Nanobiotix : 2014 Annual ResultsRead the original story w/Photo

    Tuesday Apr 14 | GlobeNewswire

    PARIS, April 14, 2015 -- NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014: Revenue increased mainly as a result of a milestone payment received from PharmaEngine to develop the Soft Tissue Sarcoma indication in the Asia-Pacific region; Expenses were impacted by Nanobiotix's R&D expansion, which has taken lead product NBTXR3 into pivotal phase II/III trials in Soft Tissue Sarcoma and pilot studies in Head and Neck cancer. Philippe MAUBERNA, Chief Financial Officer of Nanobiotix commented: " This has been an important year for Nanobiotix.

    Comment?

  4. The Best And Worst Medtech PerformersRead the original story

    Monday Apr 6 | Medical Device/Diagnostic Ind.

    Nanobiotix wants to transform therapy using its NanoXray technology portfolio. When certain nanoparticles are directly injected into cancerous tissue and radiotherapy is applied, these particles have the ability to absorb X-Ray and increase the amount of radiation to destroy diseased cells.

    Comment?

  5. Rectal Cancer Therapeutic Pipeline Assessment and Review H1 2015 Market Research ReportRead the original story

    Mar 24, 2015 | Sys-Con Media

    ... Pharma, Inc., GlaxoSmithKline plc, Hanwha Chemical Corporation, Incuron, LLC, Karyopharm Therapeutics, Inc., Nanobiotix, Peregrine Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Synta Pharmaceuticals Corp. Drug Profiles discussed in this ...

    Comment?

  6. Nanobiotix appoints CordenPharma as CMO for potential nanoparticle-based cancer treatmentRead the original story w/Photo

    Mar 19, 2015 | Drug Researcher

    The deal comes as CordenPharma plans to open a new manufacturing line at its France site, which is one of eight cGMP facilities across Europe and the US, and the new line will increase production capacity 25-fold. The new line is expected manufacture NBTXR3, Nanobiotix's lead product, which is comprised of Hafnium Oxide nanoparticles that can be injected directly into tumors.

    Comment?

  7. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Mar 17, 2015 | Business Wire

    ... IN. The report is available at 'www.fitchratings.com'. Additional information is a... )--Regulatory News : NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine ...

    Comment?

  8. Cancer Nanomedicine Marketplace Discussed by Kuick Research in...Read the original story w/Photo

    Mar 4, 2015 | PRWeb

    ... m Pharmaceuticals, Access Pharmaceuticals, Bind Biosciences, Samyang, Arrowhead Research, Epeius Biotechnologies, Nanobiotix, Nippon Kayaku, NanoCarrier, and Takeda Pharmaceutical.

    Comment?

  9. PharmaEngine, Inc. (4162) - Financial and Strategic SWOT Analysis Review - New Market ReportRead the original story

    Mar 4, 2015 | PR-inside.com

    ... the treatment of metastatic pancreatic cancer. The company is partnered with Merrimack Pharmaceuticals, Inc., and Nanobiotix S.A. It has research and development facility. The company has collaboration with Guangzhou BeBetter Medicine Technology ...

    Comment?

  10. Nanobiotix 2014 Q4 And Annual RevenuesRead the original story

    Feb 26, 2015 | BioSpace

    Paris, France, 27 February, 2015 - NANOBIOTIX - a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenues for Q4 and the annual revenues for the year ended December 31, 2014. Activity Nanobiotix revenues for the fourth quarter of 2014 include the upfront payment from the Taiwan-based PharmaEngine within the framework of the licensing contract signed in August 2012.

    Comment?

  11. Prasad receives first Innovation Impact AwardRead the original story w/Photo

    Feb 26, 2015 | UB Reporter

    ... and laser-activated nanoparticles for cancer diagnosis and treatment. This technology was licensed to UB spinoff Nanobiotix, a French publicly traded company and leader in nanomedicine that has maintained close contact with Prasad while working to ...

    Comment?

  12. New Market Research Report: Nanobiotix - Product Pipeline Review - 2014Read the original story

    Feb 23, 2015 | PR-inside.com

    This report provides comprehensive information on the current therapeutic developmental pipeline of Nanobiotix's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

    Comment?

  13. Professor Joins Nanobiotix As Scientific AdvisorRead the original story

    Feb 19, 2015 | BioSpace

    NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology , has become Scientific Advisor to Nanobiotix. Laurent Levy, CEO of Nanobiotix, commented: " We really appreciate that Professor Langer joined us as a Scientific Advisor.

    Comment?

  14. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Feb 19, 2015 | Business Wire

    ... a celle piccole, ha annunciato in data odierna che Warid Telecom, un operatore pakistano ... )--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine ...

    Comment?

  15. Professor Robert Langer joins Nanobiotix as Scientific AdvisorRead the original story

    Feb 19, 2015 | PR-inside.com

    Small but heading for the big time Professor Robert Langer joins Nanobiotix as Scientific Advisor Paris, France, 19 February, 2015 - NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology , has become Scientific Advisor to Nanobiotix. Laurent Levy, CEO of Nanobiotix, commented: "We really appreciate that Professor Langer joined us as a Scientific Advisor.

    Comment?

  16. NDDS in Cancer Therapy Market is expected to reach USD 15.9 billion in 2020Read the original story w/Photo

    Feb 2, 2015 | PRWeb

    ... in enhanced performance by the devices and are ultimately driving market growth by their increased adoption. Nanobiotix, a nanomedicine company focused on oncology, is developing NanoXray particles with the intent to enhance dose and efficacy of ...

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jan 27, 2015 | Business Wire

    The Company posted record quarterly revenue of $74.6 billion ... )--Rabobank, the world's premier bank to the food, beverage and agribusiness industry, and SF New Tech, San Francisco's largest and longest-running tech show... )--ESB Financial Corporation , the parent company of ESB Bank, today announced earnings of $1.02 per diluted share on net income of $18.2 million for ... )--Apartment Investment and Management Company announced today that its Board of Directors declared a quarterly cash dividend of $0.28 per share of Class... )--Regulatory News: NANOBIOTIX , sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une approche thA rapeutique rA volutionna... )--The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other vi... )--After a ... (more)

    Comment?

  18. Carbon nanotube maker Bio-Pact moves HQ from Arizona to CambridgeRead the original story w/Photo

    Jan 7, 2015 | Business Journal

    ... but today the company announced it will be based at 245 First St. in Cambridge. Among the others Patrick met is Nanobiotix, which announced last September it would move to Boston, and the other three are still considering coming to the state, ...

    Comment?

  19. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Jan 7, 2015 | Business Wire

    Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar Nanobiotix Moved up to a New Level: Major Clinical and Financial Progress, Broadening of Indications and Strategic Plans To Develop across Europe, Asia and the US )--Regulatory News: NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatmen... Finnair Signed a Letter of Intent: Staffpoint and GWS to Become Shareholders in a Joint Venture Focused on Regional Flying )--Regulatory News: Finnair has signed a letter of intent with StaffPoint Holding Ltd and G.W. Sohlberg Ltd., in accordance with which Flybe UK Ltd's 60 % owners... )--Regulatory News: Skanska Skanska has signed a contract with NYU Langone Medical Center to build a new medical center in New York City.

    Comment?

  20. Report Published: "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014"Read the original story

    Dec 28, 2014 | PR-inside.com

    ... Santaris Pharma A/S, CEL-SCI Corporation, OXiGENE, Inc., Takara Bio Inc., Panacea Biotec Limited, PCI Biotech AS, Nanobiotix, Acceleron Pharma, Inc., Virttu Biologics Limited, Ascenta Therapeutics,

    Comment?